Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $31,391.55 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 5,055 shares of the business’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $6.21, for a total value of $31,391.55. Following the transaction, the insider now owns 163,565 shares of the company’s stock, valued at approximately $1,015,738.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Sight Sciences Price Performance

NASDAQ:SGHT opened at $6.19 on Friday. The company has a quick ratio of 12.42, a current ratio of 13.01 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average of $6.09 and a 200 day moving average of $5.26. Sight Sciences, Inc. has a 1-year low of $1.04 and a 1-year high of $9.31.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.04). The business had revenue of $19.27 million during the quarter, compared to analysts’ expectations of $18.34 million. Sight Sciences had a negative return on equity of 44.45% and a negative net margin of 67.18%. Research analysts anticipate that Sight Sciences, Inc. will post -1.13 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Piper Sandler reiterated a “neutral” rating and set a $6.00 price objective (up previously from $5.00) on shares of Sight Sciences in a report on Friday, May 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.70.

Institutional Trading of Sight Sciences

A number of hedge funds have recently bought and sold shares of SGHT. UBS Group AG increased its holdings in shares of Sight Sciences by 20,282.6% in the 4th quarter. UBS Group AG now owns 2,895,958 shares of the company’s stock valued at $14,943,000 after acquiring an additional 2,881,750 shares during the period. Jackson Square Partners LLC boosted its position in Sight Sciences by 12.0% during the fourth quarter. Jackson Square Partners LLC now owns 1,629,746 shares of the company’s stock valued at $8,409,000 after purchasing an additional 174,737 shares in the last quarter. RTW Investments LP bought a new stake in Sight Sciences during the fourth quarter valued at about $850,000. Vanguard Group Inc. grew its stake in Sight Sciences by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock valued at $8,218,000 after purchasing an additional 81,768 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in Sight Sciences by 25.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock worth $1,991,000 after purchasing an additional 76,549 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.